MedPath

Is there a role for Helicobacter pylori eradication in the treatment of laryngopharyngeal reflux? : A double blinded randomised case controlled clinical trial - H.pylori erradication in laryngopharyngeal rteflux.

Conditions
ARYNGOPHARYNGEAL ACID REFLUX
Registration Number
EUCTR2004-001633-42-GB
Lead Sponsor
HS GRAMPIA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

LARYNGOPHARYNGEAL REFLUX AS PROVEN ON HISTORY AND FULL EXAMINATION

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1- UPPER AERODIGESTIVE TRACT MALIGNANCY
2- OTHER LARYNGEAL PATHOLOGY
3- PATIENTS CURRENTLY ON PROTON PUMP INHIBITOR THERAPY
4 - PATIENTS INVOLVED IN ANY OTHER CLINICAL TRIAL

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: TO ESTABLISH IF PATIENTS WITH LARYNGOPHARYNGEAL REFLUX HAVE HELICOBACTER PYLORI IN THERE DIGESTIVE TRACT;Secondary Objective: TO ESTABLISH IF ERADICATION OF HELICOBACTER PYLORI IMPROVES SUBJECTIVE SYMPTOMS AND OBJECTIVE SIGNS OF LARYNGOPHARYNGEAL REFLUX;Primary end point(s): 1- POSITIVE UREA BREATH TEST<br>2- REFLUX SYMPTOM INDEX SCORING SYSTEM PRE AND POST TREATMENT<br>3- REFLUX FINDINGS SCORING SYSTEM PRE AND POST TREATMENT<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath